A pioneering clinical trial is set to take place in northern New South Wales, where MDMA and nature-based therapy will be utilized to help individuals coping with post-traumatic stress disorder (PTSD) following natural disasters. With a federal government investment of $3.8 million, approximately 200 survivors of the devastating floods that struck the region in 2022 will participate in this unique trial led by James Bennett-Levy, a researcher from Southern Cross University in Lismore.
James Bennett-Levy highlighted the innovative aspect of utilizing MDMA-assisted therapy within a post-disaster scenario, describing it as a global first. The project's primary goal is to establish a leading role in climate-related mental health and well-being research, aiming to provide a comprehensive approach to recovery for those impacted by the natural disaster. The trial is designed to incorporate a "stepped care" model involving arts and nature-based group therapy initially, with the option of MDMA-assisted therapy for individuals requiring additional support.
The research project draws from previous studies conducted by the University Centre for Rural Health in Lismore following a significant flood event in 2017 and is guided by the National Disaster and Mental Health Wellbeing Framework introduced in 2023. Professor Bennett-Levy emphasized the importance of self-compassion in addressing PTSD, which can be amplified when individuals engage in self-criticism and self-blame. Recognizing the efficacy of MDMA-assisted therapy in promoting self-compassion and treating PTSD, the trial aims to offer a novel approach to mental health support for those still grappling with the aftermath of the floods in Lismore.